Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?


Currently submitted to: Journal of Medical Internet Research

Date Submitted: Oct 22, 2020
Open Peer Review Period: Oct 19, 2020 - Oct 29, 2020
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer-Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Interoperable HL7 FHIR platform to report PCR SARS-CoV-2 tests from laboratories to the Chilean government

  • Sergio Molinos; 
  • Jose Andrade; 
  • Alejandro Medina; 
  • Sonia Espinoza; 
  • Elvis Rios



Testing, traceability, and the isolation (TTI strategy) actions are a central strategy defined by WHO to contain the COVID-19 pandemic. In this sense, countries have had difficulties in counting the number of people infected with SARS-CoV-2. Errors in reporting results are a common factor as well as the lack of interoperability between laboratories and governments. Approaches aimed at sending spreadsheets via email expose patients' privacy and have increased the probability of errors due to re-typing and generate a delay in the notification of results.


Design and develop an interoperable platform to report PCR SARS-CoV-2 tests from laboratories to the Chilean government.


The methodology to design and develop the interoperable platform was comprised of six well-structured stages: 1) Creation of a minimum dataset to PCR SARS-CoV-2 tests, 2) Modeling process and endpoints where institutions interchange information, 3) Standards and interoperability design, 4) Software development, 5) Quality assurance and 6) Software implementation.


The main result was the interoperable FHIR platform to report PCR SARS-CoV-2 tests from laboratories to the Chilean government. The platform was designed, developed, tested, and implemented following a structured methodology. The platform's performance to 1,000 requests resulted in a response time of 240 milliseconds, throughput was 28.3 requests per second, and the process management time was 131 milliseconds. The platform has availability of 99.9 %. The security was implemented with JSON Web Token (JWT) to ensure confidentiality, authorization, and authentication. All the PCR SARS-CoV-2 tests were accessible through an Application Programming Interface (API) gateway with valid credentials and the right access control list.


The platform was implemented and is currently being used by UC Christus Laboratory. The platform is secure. It was tested adequately for confidentiality, secure authorization, authentication, and message integrity. This platform simplifies the reporting of PCR SARS-CoV-2 tests and reduces the time and probability of mistakes in counting positive cases. The interoperable solution with FHIR is working successfully and is open for the community, laboratories, and any institution that needs to report PCR SARS-CoV-2 tests.


Please cite as:

Molinos S, Andrade J, Medina A, Espinoza S, Rios E

Interoperable HL7 FHIR platform to report PCR SARS-CoV-2 tests from laboratories to the Chilean government

JMIR Preprints. 22/10/2020:25149

DOI: 10.2196/preprints.25149


Download PDF

Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.